Charles C. Guo

35.8k total citations · 3 hit papers
136 papers, 5.4k citations indexed

About

Charles C. Guo is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Charles C. Guo has authored 136 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Surgery, 52 papers in Pulmonary and Respiratory Medicine and 31 papers in Molecular Biology. Recurrent topics in Charles C. Guo's work include Bladder and Urothelial Cancer Treatments (68 papers), Urinary and Genital Oncology Studies (63 papers) and Testicular diseases and treatments (19 papers). Charles C. Guo is often cited by papers focused on Bladder and Urothelial Cancer Treatments (68 papers), Urinary and Genital Oncology Studies (63 papers) and Testicular diseases and treatments (19 papers). Charles C. Guo collaborates with scholars based in United States, Canada and United Kingdom. Charles C. Guo's co-authors include Bogdan Czerniak, Jonathan I. Epstein, Ashish M. Kamat, Wassim Kassouf, Seth P. Lerner, Woonyoung Choi, Yair Lotan, Noah M. Hahn, Jason A. Efstathiou and Per‐Uno Malmström and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Charles C. Guo

124 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bladder cancer

2016 1.0k citations Ashish M. Kamat, Charles C. Guo et al. profile →
WHO Classification of of Tumours of the Urinary System and Male Genital Organs

2016 587 citations Charles C. Guo et al. profile →
Molecular profile of bladder cancer progression to clinically aggressive subtypes

2024 38 citations Charles C. Guo, David J. McConkey et al. profile →

Peers

Charles C. Guo

SURGE

PRM

ONCOL

Didier Jacqmin France

Jörg Hennenlotter Germany

Maria Rosaria Raspollini Italy

Mark Schoenberg United States

Shuji Mikami Japan

Mathieu Rouanne France

Fredrik Liedberg Sweden

Juan Moróte Spain

Hiro‐omi Kanayama Japan

Paul L. Crispen United States

Didier Jacqmin France

Charles C. Guo

1.4k ×0.5

SURGE

3.0k ×1.5

PRM

2.1k ×1.3

609 ×0.6

ONCOL

740 ×1.0

Citations per year, relative to Charles C. Guo Charles C. Guo (= 1×) peers Didier Jacqmin

Countries citing papers authored by Charles C. Guo

Since Specialization

Citations

This map shows the geographic impact of Charles C. Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles C. Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles C. Guo more than expected).

Fields of papers citing papers by Charles C. Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles C. Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles C. Guo. The network helps show where Charles C. Guo may publish in the future.

Co-authorship network of co-authors of Charles C. Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Charles C. Guo. A scholar is included among the top collaborators of Charles C. Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles C. Guo. Charles C. Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zheng, Lan, Georges Tabet, Charles C. Guo, et al.. (2025). Clinicopathological study of 34 cases of clear cell adenocarcinoma of the urinary tract and diagnostic value of SOX 17 in its differential diagnosis. Human Pathology. 157. 105767–105767. 1 indexed citations

Wilson, Nathaniel R., Lianchun Xiao, Jianjun Gao, et al.. (2024). Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO).. Journal of Clinical Oncology. 42(16_suppl). 4605–4605. 1 indexed citations

Guo, Ming, et al.. (2024). Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. American Journal of Clinical Pathology. 162(5). 492–499. 1 indexed citations

Johns, Andrew, Matthew T. Campbell, Ahmet Murat Aydın, et al.. (2024). Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. Journal of Clinical Medicine. 13(12). 3436–3436.

Guo, Charles C. & Bogdan Czerniak. (2023). Reprint of: somatic-type malignancies in testicular germ cell tumors. Human Pathology. 133. 102–114. 2 indexed citations

Carruthers, Nicholas J., et al.. (2023). Mercury intoxication disrupts tonic signaling in B cells, and may promote autoimmunity due to abnormal phosphorylation of STIM-1 and other autoimmunity risk associated phosphoproteins involved in BCR signaling. Toxicology and Applied Pharmacology. 474. 116607–116607. 1 indexed citations

Guo, Charles C. & Bogdan Czerniak. (2023). Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors. PubMed. 0(0). 0–0. 6 indexed citations

Alhalabi, Omar, Rahul A. Sheth, Amishi Y. Shah, et al.. (2023). 660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC). SHILAP Revista de lepidopterología. A752–A752. 1 indexed citations

Fan, Jiaming, et al.. (2023). Testicular Germ Cell Tumors with Somatic-type Malignancy. 0(0). 0–0. 2 indexed citations

10.

Alhalabi, Omar, Wei Qiao, Amishi Y. Shah, et al.. (2023). Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV).. Journal of Clinical Oncology. 41(16_suppl). e16618–e16618.

11.

Hensley, Patrick J., Kelly K. Bree, Anil K. Sood, et al.. (2022). Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urologic Oncology Seminars and Original Investigations. 41(2). 108.e11–108.e17. 1 indexed citations

12.

Hensley, Patrick J., Kelly K. Bree, Matthew T. Campbell, et al.. (2021). Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. The Journal of Urology. 206(5). 1258–1267. 12 indexed citations

13.

Hensley, Patrick J., Kelly K. Bree, Charles C. Guo, et al.. (2021). Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. British Journal of Urology. 130(5). 604–610. 3 indexed citations

14.

Petros, Firas G., Roger Li, Bryan Fellman, et al.. (2019). Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 37(6). 354.e19–354.e26. 4 indexed citations

15.

Li, Roger, Michael Metcalfe, William Tabayoyong, et al.. (2018). Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. European Urology Oncology. 2(3). 286–293. 9 indexed citations

16.

Metcalfe, Michael, James E. Ferguson, Roger Li, et al.. (2017). Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. European Urology Focus. 3(6). 577–583. 10 indexed citations

17.

Murugan, Paari, Priya Rao, Pheroze Tamboli, Bogdan Czerniak, & Charles C. Guo. (2017). Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. Pathology & Oncology Research. 24(1). 153–159. 26 indexed citations

18.

Guo, Charles C., et al.. (2015). Sexual dimorphism in miR-210 expression and mitochondrial dysfunction in the placenta with maternal obesity. International Journal of Obesity. 39(8). 1274–1281. 89 indexed citations

19.

Muralimanoharan, Sribalasubashini, et al.. (2012). MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta. 33(10). 816–823. 203 indexed citations

20.

Brimo, Fadi, et al.. (2010). Renal Epithelioid Angiomyolipoma With Atypia: A Series of 40 Cases With Emphasis on Clinicopathologic Prognostic Indicators of Malignancy. The American Journal of Surgical Pathology. 34(5). 715–722. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact